FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology, namely to ophthalmology and pharmacogenetics, and can be used in selecting a therapy in patients with exudative ("wet") and "dry" forms of age-related macular degeneration (AMD).
EFFECT: method provides selection of adequate therapy for patients with various forms of AMD by analyzing polymorphisms of a certain group of genes that determine the choice of a basic preparation in the therapy, which enables therapeutic effect excluding possibility of complications related to individual peculiarities of organism of each individual patient.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
| METHOD FOR DETERMINING INDICATIONS FOR ANTIANGIOGENIC THERAPY IN CASE OF SUSPICION OF WET FORM OF AGE-RELATED MACULAR DEGENERATION | 2021 |
|
RU2758662C1 |
| METHOD FOR INHIBITING THE PROGRESSION OF THE "DRY" FORM OF AGE-RELATED MACULAR DEGENERATION IN ELDERLY PATIENTS | 2020 |
|
RU2755890C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF AVASCULAR AND VASCULAR SEROUS DETACHMENT OF RETINAL PIGMENT EPITHELIUM (RPE) IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION | 2021 |
|
RU2763639C1 |
| METHOD FOR TREATMENT OF CATARACT IN PATIENTS WITH ACTIVE NEOVASCULAR DISEASES OF MACULA | 2017 |
|
RU2659144C1 |
| METHOD FOR PREDICTION OF UNFAVORABLE RESPONSE TO ANTI-VEGF THERAPY IN MACULAR NEOVASCULARISATION BY BODY MASS INDEX | 2023 |
|
RU2821261C1 |
| METHOD FOR SURGICAL TREATMENT OF WET MACULAR DEGENERATION COMPLICATED BY SECONDARY EPIRETINAL MEMBRANE | 2021 |
|
RU2758026C1 |
| METHOD OF PREDICTING RESPONSE TO ANTI-VEGF THERAPY IN MACULAR NEOVASCULARIZATION | 2023 |
|
RU2810939C1 |
| METHOD FOR PREDICTING RESPONSE TO REPEATED ANTI-VEGF THERAPY IN CHOROIDAL NEOVASCULARIZATION IN AMD | 2022 |
|
RU2788971C1 |
| PREDICTION OF PROGRESSION OF AGE-RELATED MACULAR DYSTROPHY TO LATE STAGE BY MEANS OF POLYGENE INDICATOR | 2011 |
|
RU2593954C2 |
